Related changes
Jump to navigation
Jump to search
Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
1 June 2024
| m 04:03 | Nivolumab (Opdivo) diffhist +210 Jwarner talk contribs →Malignant pleural mesothelioma | ||||
| m 04:01 | Brentuximab vedotin (Adcetris) diffhist +134 Jwarner talk contribs →History of changes in PMDA indication | ||||
| m 03:50 | Pembrolizumab (Keytruda) diffhist +203 Jwarner talk contribs →Renal cell carcinoma | ||||
| m 03:43 | Cytarabine (Ara-C) diffhist +156 Jwarner talk contribs →History of changes in PMDA indication | ||||
|
|
m 03:26 | Stub 2 changes history +16,468 [Jwarner (2×)] | |||
| m |
|
03:26 (cur | prev) +504 Jwarner talk contribs →Regimens that contain experimental (unapproved) drugs | |||
| m |
|
03:25 (cur | prev) +15,964 Jwarner talk contribs →Regimens composed solely of approved drugs | |||
28 May 2024
| m 23:12 | Allogeneic HSCT diffhist +605 Jwarner talk contribs →References | ||||
26 May 2024
| m 12:55 | Rituximab (Rituxan) diffhist -13 Jwarner talk contribs →Also known as | ||||